Ohio is currently considering a statewide ban on kratom, but a recent move by the Board of Pharmacy to delay the decision signals recognition of an important distinction: not all kratom products are the same. Governor DeWine’s recommendation would have banned natural kratom leaf alongside newer, more dangerous synthetic derivatives of 7-hydroxymitragynine (7-OH), despite much of the harm and risk stemming from these concentrated synthetic substances, not the traditional plant.
Florida and the FDA offer a model for a targeted approach by restricting 7-OH levels and leaving natural kratom leaf available to consumers. Clinical studies show natural leaf kratom has a safer profile compared to the addictive risks of synthetic 7-OH, which is created by chemical extraction and manipulation and linked to opioid-like effects.
Experts advocate for smart regulation, including age restrictions and alkaloid content limits, to keep consumers safe without eliminating natural kratom. For additional information, visit the source at the Canton Repository.